Comparison of serum sIL-2R and LDH levels in patients with                    intravascular large B-cell lymphoma and patients with advanced stage diffuse                    large B-cell lymphoma

Yuki Hirami; Midori Filiz Nishimura; Tomohiro Urata; Michiko Morimoto; Yukina Maekawa; Tadashi Yoshino; Yoshito Nishimura; Yasuharu Sato

doi:10.3960/jslrt.22043

Original Article

Comparison of serum sIL-2R and LDH levels in patients with intravascular large B-cell lymphoma and patients with advanced stage diffuse large B-cell lymphoma

Yuki Hirami, Midori Filiz Nishimura , Tomohiro Urata, Michiko Morimoto, Yukina Maekawa, Tadashi Yoshino, Yoshito Nishimura, Yasuharu Sato

Author information

Yuki Hirami
Department of Nursing, Okayama University Graduate School of Health Sciences, Okayama, Japan,
Midori Filiz Nishimura Corresponding author
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,
Tomohiro Urata
Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan,
Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan,
Michiko Morimoto
Department of Nursing, Okayama University Graduate School of Health Sciences, Okayama, Japan,
Yukina Maekawa
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,
Tadashi Yoshino
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,
Yoshito Nishimura
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,
Department of Medicine, John A. Burns School of Medicine, University of Hawai’i, Honolulu, HI, USA
Yasuharu Sato
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,

Keywords: intravascular large B-cell lymphoma, diffuse large B-cell lymphoma, soluble interleukin-2 receptor, lactate dehydrogenase, B symptoms

JOURNAL OPEN ACCESS

2022 Volume 63 Issue 1 Pages 25-31

DOI https://doi.org/10.3960/jslrt.22043

Browse “Advance online publication” version

Details

Abstract

Intravascular large B-cell lymphoma (IVL) is a rare type of lymphoma characterized by tumor growth selectively within the vessels. The 5^th edition of the World Health Organization classification defines IVL as a large B-cell lymphoma, the same as diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Since the clinical manifestations of IVL are nonspecific, the diagnosis is time-consuming, and the course is often fatal. Serum soluble interleukin-2 receptor (sIL-2R) and serum lactate dehydrogenase (LDH) levels are known to be elevated in a variety of lymphomas. However, the mechanism of sIL-2R elevation in B-cell lymphomas is not fully understood. In this study, we analyzed the serum level of laboratory findings, including sIL-2R and LDH, as well as the presence of B symptoms in 39 patients with IVL, and compared them with 56 patients with stage IV DLBCL. Both sIL-2R and LDH levels were significantly higher in IVL than in DLBCL (p = 0.035 and p = 0.002, respectively). In IVL, there were no significant differences in both sIL-2R and LDH levels between patients with and without B symptoms (p = 0.206 and p = 0.441, respectively). However, in DLBCL, both sIL-2R and LDH levels were significantly higher in the presence of B symptoms (p = 0.001 and p < 0.001, respectively). The high sIL-2R and LDH levels in IVL may be related to the peripheral blood microenvironment, but further studies are needed to verify this.

Corresponding author

Register with J-STAGE for free!